Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | WRN | Q14191 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6655879 | 0.98 | GABBR2 (0.51) | GABBR2GABBR1F2DAOMEN1 | |
| SCHEMBL11694787 | 0.84 | GABBR2 (0.49) | GABBR2GABBR1F2DAOKMT2A | |
| SCHEMBL11560650 | 0.79 | GABBR2 (0.49) | GABBR2GABBR1F2DAOMEN1 | |
| SCHEMBL11560654 | 0.79 | GABBR2 (0.49) | GABBR2GABBR1F2DAOMEN1 | |
| SCHEMBL3615972 | 0.78 | GABBR2 (0.44) | GABBR2GABBR1F2DAOMEN1 | |
| SCHEMBL5926065 | 0.78 | GABBR2 (0.47) | GABBR2GABBR1F2DAOMEN1 | |
| SCHEMBL23972469 | 0.78 | GABBR2 (0.50) | GABBR2GABBR1F2DAOKMT2A | |
| SCHEMBL11518982 | 0.78 | ALOX5 (0.51) | DAOMEN1KMT2ACYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL2819034 | 0.77 | GABBR2 (0.43) | GABBR2GABBR1F2DAOMEN1 | |
| SCHEMBL4240529 | 0.76 | DAO (0.45) | DAOMEN1KMT2AGSK3BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094272-B1 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| EP-1751119-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| US-4155905-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4088816-A | BACTERICIDES | E. R. SQUIBB & SONS, INC. (US) | 1978-05-09 | — | — | US | disclosed |
| US-4077967-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4061851-A | 7-Amino-7-arylthio cephalosporins | E. R. SQUIBB & SONS, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4061629-A | 6-Amino-6-arylthio penicillanic acids and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4029669-A | 6-Benzalimino-6-arylthio penicillanic acids and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1977-06-14 | — | — | US | disclosed |
| US-4026886-A | 7-Acyl-7-arylthiocephalosporins | E. R. SQUIBB & SONS, INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-3965093-A | 6-Arylthio penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3954744-A | ANTIBACTERIAL | E. R. SQUIBB & SONS, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | VIP, CCKBR, HRH2 | GABBR2 1197/4885GABBR1 1314/4885F2 248/4885 |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | TBXA2R, F2R, PTGER1 | GABBR2 2434/4885GABBR1 2362/4885F2 65/4885 |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, PTAFR, PLAT | GABBR2 327/4885GABBR1 316/4885F2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.